ProCE Banner Activity

A Year in Review and a Look to the Future: BTKi in CLL and MCL

Conference Coverage
Podcast Episodes

Expert faculty discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, as well as anticipated data from ASH 2023 and the current and potential impact on practice.

Released: November 20, 2023

Share

Faculty

Ana Marin-Niebla

Ana Marin-Niebla, MD, PhD

Hematology Consultant, Lymphoma Unit
Vall d'Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d'Hebron
Barcelona, Spain

Stephan Stilgenbauer

Stephan Stilgenbauer, MD

Medical Director, Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL
Department of Internal Medicine III
Comprehensive Cancer Center Ulm
University Medical Center Ulm
Ulm, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Ana Marin-Niebla, MD, PhD

Hematology Consultant, Lymphoma Unit
Vall d'Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d'Hebron
Barcelona, Spain

Ana Marin-Niebla, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Gilead Kite, Janssen, Lilly, Takeda,

Stephan Stilgenbauer, MD

Medical Director, Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL
Department of Internal Medicine III
Comprehensive Cancer Center Ulm
University Medical Center Ulm
Ulm, Germany

Stephan Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Janssen, Lilly, Novartis, Sunesis.